Inhaled Budesonide for Altitude Illness Prevention

Summary

A randomized, double-blinded study administering budesonide, a medication to reduce inflammation in the lungs, to healthy volunteers to examine effects on altitude illness prevention by spending 18 hours overnight at 14,000 ft elevation.

Timeline

Start

2017-03-06

Primary completion

2017-03-06

Completion

2017-03-06

Outcome

Outcome not reported

Stopped (Enrollment): “Stopped prior to enrollment per PI and DSMB decision.”

Drugs

Indications